Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study

  28 August 2020

Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. The authors determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19.

The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.

Author(s): Valerie M Vaughn, MD, MSc, Tejal Gandhi, MD, Lindsay A Petty, MD, Payal K Patel, MD, MPH, Hallie C Prescott, MD, MSc, Anurag N Malani, MD, David Ratz, MS, Elizabeth McLaughlin, MS, RN, Vineet Chopra, MD, MSc, Scott A Flanders, MD
Effective Surveillance   Healthy Patients  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!